Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and false negative

Won Sriwijitalai1; Viroj Wiwanitkit2
1. TWS Medical Center, Bangkok Thailand
2.Honorary professor, Dr DY Patil University, Pune, India

Correspondence

Won Sriwijitalai
TWS Medical Center, Bangkok Thailand

Email: wonsriwi@gmail.com

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and false negative

Dear Editor, we read the publication on “Early Direct Antiglobulin Test (DAT) Negativity after Bendamustine and Rituximab (BR) Treatment in Chronic Lymphocytic Leukemia (CLL): Two Cases [1].” Eren and Suyanı noted that “BR seems to be an important treatment of choice in terms of eliminating the poor prognostic factor of DAT positivity and assuring safe cessation of steroid treatment due to rapid achievement of DAT negativity [1].” The interesting observation on negative DAT test should be discussed. There is another possibility that Eren and Suyanı did not mentioned. In the report, Eren and Suyanı noted that “no titer provided [1]”. Whether the negative result is a false negative result should be discussed. For DAT test, the prozone phenomenon is observable and it is important to have this phenomenon in interpretation on unexpected false negative DAT test [2 - 4].

Conflict of interest: None

References